

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this document, makes no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this document.*



## **APPOINTMENT OF EXECUTIVE DIRECTORS**

The Board of Directors (the “Board”) of China Pharmaceutical Group Limited (the “Company”) is pleased to announce the appointment of Mr. Wang Huaiyu and Mr. Lu Jianmin as executive directors of the Company with effect from 8 October 2010.

Mr. Wang Huaiyu, aged 47, joined a member of our Group in 2002 and is currently the director and general manager of a member of the Group. Mr. Wang holds a bachelor degree in microbiology and biochemistry from Hebei University and has more than 20 years of technical and management experience in the pharmaceutical industry. Mr. Wang has not held any directorship in any public listed companies in the last three years.

Mr. Lu Jianmin, aged 52, joined a member of our Group in 1990 and is currently the president of the Group’s finished drugs division. Mr. Lu has more than 20 years of technical and management experience in the pharmaceutical industry. Mr. Lu has not held any directorship in any public listed companies in the last three years.

There is no service contract entered into between the Company and Mr. Wang and Mr. Lu. They are not appointed for a specific term but are subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the articles and association of the Company. Each of Mr. Wang and Mr. Lu is entitled to receive a monthly salary of RMB50,000 and an annual director’s fee of HK\$60,000. They are also eligible to receive performance related discretionary bonus to be determined by the Board. Their emoluments were determined having giving

consideration to the prevailing market practice, the Company's remuneration policy and their level of responsibility.

As at the date of this announcement, Mr. Wang and Mr. Lu do not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance nor any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company. Save as disclosed above, Mr. Wang and Mr. Lu confirmed that there is no other information required to be disclosed under Rule 13.51(2) of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited and there is no other matter relating to their appointment which needs to be brought to the attention of the shareholders of the Company.

By order of the Board  
**China Pharmaceutical Group Limited**  
**Cai Dongchen**  
*Chairman*

Hong Kong, 8 October 2010

*As at the date of this announcement, the Board of the Company comprises Mr. Cai Dongchen, Mr. Feng Zhenying, Mr. Chak Kin Man, Mr. Pan Weidong, Mr. Zhao John Huan, Mr. Wang Shunlong, Mr. Wang Huaiyu and Mr. Lu Jianmin as executive directors; Mr. Lee Ka Sze, Carmelo as non-executive director; and Mr. Huo Zhenxing, Mr. Qi Moujia, Mr. Guo Shichang and Mr. Chan Siu Keung, Leonard as independent non-executive directors.*